China Resources Pharmaceutical Group Limited

SEHK:3320 Voorraadrapport

Marktkapitalisatie: HK$34.8b

China Resources Pharmaceutical Group Toekomstige groei

Future criteriumcontroles 2/6

China Resources Pharmaceutical Group is forecast to grow earnings and revenue by 7.5% and 7.8% per annum respectively. EPS is expected to grow by 7.2% per annum. Return on equity is forecast to be 6% in 3 years.

Belangrijke informatie

7.5%

Groei van de winst

7.2%

Groei van de winst per aandeel

Pharmaceuticals winstgroei11.1%
Inkomstengroei7.8%
Toekomstig rendement op eigen vermogen6.0%
Dekking van analisten

Good

Laatst bijgewerkt04 Nov 2024

Recente toekomstige groei-updates

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Winst- en omzetgroeiprognoses

SEHK:3320 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026315,6575,0949,01214,3138
12/31/2025287,1854,6557,49811,47510
12/31/2024263,0734,2497,28216,6409
6/30/2024250,4833,77715,27818,300N/A
3/31/2024247,5933,81613,91416,925N/A
12/31/2023244,7043,85412,55015,550N/A
9/30/2023232,5643,57310,22312,883N/A
6/30/2023224,6563,3827,69710,053N/A
3/31/2023224,5873,5187,84710,355N/A
12/31/2022218,1833,5008,23910,821N/A
9/30/2022221,4873,7247,43110,371N/A
6/30/2022211,7883,7196,2409,347N/A
3/31/2022196,2263,2886,9359,628N/A
12/31/2021193,0213,0728,00910,468N/A
9/30/2021191,4952,8695,9588,155N/A
6/30/2021187,5542,6263,7925,694N/A
3/31/2021179,5122,7204,5216,344N/A
12/31/2020168,7622,7765,1946,910N/A
9/30/2020171,8732,6836,9868,696N/A
6/30/2020174,9562,5788,91410,616N/A
3/31/2020181,0542,7937,2729,038N/A
12/31/2019182,6902,9375,4887,274N/A
9/30/2019183,4173,6705,6587,406N/A
6/30/2019173,9384,1875,5107,124N/A
3/31/2019165,6793,7375,3706,990N/A
12/31/2018166,6263,4945,5287,244N/A
9/30/2018163,7343,4664,9846,419N/A
6/30/2018154,8523,3094,2765,387N/A
3/31/2018142,2962,959N/A4,493N/A
12/31/2017143,6882,901N/A4,045N/A
9/30/2017143,2522,759N/A1,486N/A
6/30/2017142,2762,602N/A-1,189N/A
3/31/2017142,0032,577N/A1,219N/A
12/31/2016140,3162,526N/A3,689N/A
9/30/2016132,2532,161N/A4,391N/A
6/30/2016129,3131,889N/A5,222N/A
3/31/2016123,7702,103N/A5,027N/A
12/31/2015122,7852,388N/A5,017N/A
12/31/2014108,5752,116N/A3,349N/A
12/31/201391,3132,061N/A3,203N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 3320's forecast earnings growth (7.5% per year) is above the savings rate (2.3%).

Winst versus markt: 3320's earnings (7.5% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).

Hoge groeiwinsten: 3320's earnings are forecast to grow, but not significantly.

Omzet versus markt: 3320's revenue (7.8% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Hoge groei-inkomsten: 3320's revenue (7.8% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: 3320's Return on Equity is forecast to be low in 3 years time (6%).


Ontdek groeibedrijven